This inhibition, which was attributed to downregulation of Abca1 gene and ABCA1 protein expression, suggested that PCSK9 can also have extrahepatic effects that may influence relevant steps in the pathogenesis of atherosclerosis (56). The gene discussed is ABCA1; the disease is atherosclerosis.